---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-026982"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-06-30T21:16:14+00:00"
generated_at: "2026-06-30T21:18:07.024392+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma: John Militello resigns as Principal Accounting Officer; Joseph Manhede appointed

## Summary
- John Militello resigns as VP Finance, Senior Controller, Treasurer and Principal Accounting Officer effective July 7, 2026 to pursue other opportunities.
- Joseph Manhede, age 48, appointed as Principal Accounting Officer effective July 8, 2026; previously Associate VP Corporate Controller since April 2026.
- Manhede previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife, and Celator; began career at Deloitte as Audit Manager.
- No new compensatory arrangements entered into with Manhede in connection with the appointment; no family relationships or reportable transactions.

## SEC filing metadata
- accession: 0001140361-26-026982
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-06-30T21:16:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126026982/0001140361-26-026982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126026982/ef20077135_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-026982
- JSON: https://secwatch.observer/filing/0001140361-26-026982.json
- Plain text: https://secwatch.observer/filing/0001140361-26-026982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.